The size of the Colorectal Cancer Market in the Asia Pacific was worth $3.28 billion in 2019 and estimated to be growing at a CAGR of 3.40%, to reach $3.88 billion by 2024.
Though there has been substantial development in science and technology to combat cancer, it continues to threaten lives across the globe.
Colorectal cancer results due to unrestrained cell growth that occurs in the appendix, colon, and the rectum region. Colorectal cancer is identified with a biopsy, which then followed by medical imaging to know its extent. Depending on the stage and how much cancer has expanded, a combination of radiation therapy, chemotherapy, and targeted therapy is recommended by most oncologists.
The growth of the Asia-Pacific Colorectal Cancer market is mainly due to the rise in the aging population, and increasing awareness towards Colorectal Cancer.
However, poor accessibility of proper care, volatile economies and lack of awareness in this part of the world are the key factors hindering the growth of the market in this region.
This research report segmented and sub-segmented into the following categories:
Regionally, The Asia-Pacific region is projected to grow at the highest CAGR during the forecast period due to reasons such as rising aging population and increasing participation of several private & public establishments to organize awareness programs on Colorectal Cancer. China is the largest market for Colorectal Cancer in this region followed by India. Indonesia, Vietnam, and Malaysia, are some of the significant players in this market.
Promising companies in the APAC Colorectal Cancer Market profiled in this report are Abbott Diagnostics, Alere, Beckman Coulter, Clinical Genomics, Companion Dx, Hoffmann La Roche, Debiopharm Group and Vaccinogen BD
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Diagnosis
5.1.1 Digital Rectal Examination
5.1.2 Faecal Occult Blood Test
5.1.3 Flexible Sigmoidoscopy
5.1.4 Colonoscopy
5.1.5 Virtual Colonoscopy
5.2 By Treatment
5.2.1 Surgery and Radiation Therapy
5.2.2 Chemotherapy
5.2.3 Targeted Therapies
5.2.4 Resistance to Pharmacological Therapies
6. Geographical Analysis
6.3 Asia-Pacific
6.1 Introduction
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Abbott Diagnostics
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Alere
8.3 Beckman Coulter
8.4 Clinical Genomics
8.5 Companion Dx
8.6 Hoffmann La Roche
8.7 Debiopharm Group
8.8 Vaccinogen BD
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Expert Opinions
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
